0.9-1.8 ng/dL

Units:   µIU/mL
   Age                                 Reference Range
0 – 5 days                            0.70 – 15.20
5 days – 2 months               0.70 – 11.00
2 months – 11 months         0.70 – 8.40
11 months – 5 years            0.70 – 6.00
5 years – 10 years               0.60 – 4.80
10 years – 19 years             0.50 – 4.30
>19 years – 150 years          0.27 – 4.20

Anti-Tg

≤115 IU/mL: Negative
>115 IU/mL: Positive

TPO

≤34 IU/mL: Negative
>34 IU/mL: Positive

This result was obtained using the Roche ELECSYS electrochemiluminescence assay. Results obtained using different assay methods cannot be directly compared due to differences in immunoassay design and antibody epitope recognition

≤34 IU/mL: Negative
>34 IU/mL: Positive

0.00-0.55 IU/L

≤ 1.75 IU/L

See Individual tests

BRAF Mutation Analysis, Papillary Thyroid Cancer

 

RAS Mutation Analysis, Thyroid Cancer
 

RET/PTC Rearrangement, Thyroid Cancer
 

PAX8/PPAR[gamma] Translocation, Thyroid Cancer
 

See Report

15-65 pg/mL

Reference Range - 10-65 pg/mL

Levels >1000 pg/mL suggestive of pathologic parathyroid lesion

Reference Range: Hospital patients 1.15 – 1.33 mmol/L
           Outreach( to LabCorp) 4.5 – 5.6 mg/dL

This result was obtained using the Roche ELECSYS electrochemiluminescence assay. Results obtained using different assay methods cannot be directly compared due to differences in immunoassay design and antibody epitope recognition.

Note: The presence of thyroglobulin autoantibodies can interfere with the measurement of serum thyroglobulin.

American Thyroid Association Therapy Response Classification Threshold Values Among Patients With DTC

Excellent Response = Suppressed Tg < 0.2 ng/mL

Indeterminate Response = Suppressed Tg 0.2 to < 1.0 ng/mL

Biochemical Incomplete Response = Suppressed Tg ≥ 1.0 ng/mL

Reference: Thyroid 26.1 (2016): 1-133. https://doi.org/10.1089/thy.2015.0020

Further Information:

Requisition

If an EPIC order is not used, the Cytopathology requisition form must be completed with the following information:

Name and location of the referring clinician

Source of specimen, include side and/or lobe, if applicable

Specimen collection date.

Patient demographics: name, address, gender, and date of birth

Test(s) ordered

ICD-10 code (reason for test)

Significant patient history

For thyroids- if reflex for molecular is needed, indicate test type (Thyroseq, Afirma, Quest) and reflex conditions. A separate requisition for Thyroseq and Afirma must accompany the vials.

≤115 IU/mL: Negative
>115 IU/mL: Positive

This result was obtained using the Roche Elecsys anti-Tg assay. Results obtained using different assay methods cannot be directly compared due to differences in immunoassay design and antibody epitope recognition.

≤0.02 nmol/L

Reference values apply to all ages.

137-370 µg/L
 
Note: Reference interval reflects flavinadeninedinucleotide (FAD), that accounts for approximately 90% of the total riboflavin in whole blood.

See Report

See Report

Healthy individuals with intact, functioning thyroid: < or = 33 ng/mL
The reference ranges listed below, however, are for thyroid cancer follow up of athyrotic patients and apply to unstimulated and stimulated thyroglobulin (Tg) measurements. Ranges are based on best practice guidelines and the literature, which includes Mayo Clinic studies, and represent clinical decision levels.
 
Decision levels for thyroid cancer patients, who are not completely athyrotic (ie, patient has some remnant normal thyroid tissue), have not been established, but are likely to be somewhat higher: remnant normal thyroid tissue contributes to serum Tg concentrations 0.2-1.0 ng/mL per gram of remnant tissue, depending on the thyroid-stimulating hormone (TSH) level.
 
Tg <0.2 ng/mL: Tg levels must be interpreted in the context of TSH levels, serial Tg measurements, and radioiodine ablation status. Undetectable Tg levels in athyrotic individuals on suppression therapy indicate a minimal risk (<1%-2%) of clinically detectable recurrent papillary/follicular thyroid cancer.
 
Tg > or = 0.2 ng/mL to 2.0 ng/mL: Tg levels must be interpreted in the context of TSH levels, serial Tg measurements, and radioiodine ablation status. Tg levels of 0.2-2.0 ng/mL in athyrotic individuals on suppressive therapy indicate a low risk of clinically detectable recurrent papillary/follicular thyroid cancer.
 
Tg 2.1 ng/mL to 9.9 ng/mL: Tg levels must be interpreted in the context of TSH levels, serial Tg measurements and radioiodine ablation status. Tg levels of 2.1-9.9 ng/mL in athyrotic individuals on suppression therapy indicate an increased risk of clinically detectable recurrent papillary/follicular thyroid cancer.
 
Tg > or = 10 ng/mL: Tg levels must be interpreted in the context of TSH levels, serial Tg measurements and radioiodine ablation status. Tg levels of 10 ng/mL or above in athyrotic individuals on suppressive therapy indicate a significant (>25%) risk of clinically detectable recurrent papillary/follicular thyroid cancer.

See Report

Interpretatoin:  This profile is consistent with an autoimmune central nervous system disorder.

Negative for BRAF V600 Mutations

LIMITATIONS: This assay is qualitative and is not intended to detect minimal residual disease. Although this assay detects BRAF V600E, V600K, V600R, V600M, and V600D mutations, it does not distinguish between BRAF mutations occurring on the same nucleotide, i.e., the V600E/D or V600K/R/M mutations.This assay does not detect mutations or alterations in other regions of the BRAF gene. Mutations present below the limit of detection of the assay (1%) might not be detected.